Inc. has been awarded a series of contracts with a top multinational pharmaceutical
company (the "Sponsor") to provide essential laboratory data for a global
Phase I and Phase II cholesterol-treatment program. These contracts are part of
a series of eight contracts related to clinical trials that form part of a global
development program for an innovative approach for the prevention and treatment
of dyslipidemia, atherosclerosis, and coronary heart disease. PBI will provide
the Sponsor with cholesterol, lipid, and inflammatory marker testing on samples
collected to support the Sponsor's clinical development program.